abstract: OBJECTIVE: @entity1 present a rare but important physical and emotional challenge for @entity0 and parents. Radiological imaging is important for accurate diagnosis, to aid decision making and to monitor changes in the growing hand. The goal of any treatment is to help the @entity0 achieve his/her maximum potential, to provide a useful hand with attention to cosmesis. We investigated the range of @entity1 imaged in a tertiary referral centre. We examined the timing of imaging and the key clinical questions. METHODS: The radiology imaging system was searched retrospectively for radiographs of @entity1 over a 6-year period. The images were reviewed and @entity0 demographics, diagnosis and other imaging recorded. RESULTS: Over 6  years, 85 @entity0 had imaging. Twenty-three @entity0 had bilateral problems and 11 had recognised syndromes. The most common abnormalities imaged were duplicated thumbs (28  %), followed by syndactyly (18  %). @entity0 were first imaged as early as 1  day old, with the median age of initial imaging 12  months. CONCLUSIONS: Thumb duplication and syndactyly are the most common conditions for which radiographs are requested at our hospital, although overall syndactyly is considered the most common @entity1 . For a variety of reasons, @entity0 are often imaged very early, before review by the Specialist in @entity0 's Hand Surgery (despite surgery being unlikely before 1  year of age.) We discuss the classification systems and specific issues that hand surgeons want to know from the radiologists.

title: Radiological imaging of XXXX -a 6-year single-centre experience and what the hand surgeons want to know.

answer: @entity1


abstract: The reproducibility of coronary sinus blood flow (CSBF) (thermodilution technique) and myocardial metabolism (exchange of @entity1 , @entity5 , free @entity7 , @entity2 , @entity8 , @entity9 and @entity4 ) during two identical pacing periods separated by 45 min were studied in eight @entity0 with chronic @entity3 . The mean of the individual difference (delta-values) between values during the first (T1) and second (T2) test, at corresponding times (rest, pacing and after 3-5 min of recovery), were calculated and expressed as a percentage of the resting level of each parameter in order to assess their reproducibility. All @entity0 experienced @entity6 during both pacing sessions, and pacetime to onset of symptoms did not differ between the tests. Group values for haemodynamics and exchange of metabolites were acceptably reproducible throughout the period under study. Mean delta-values of CSBF ranged from 10% to 16% and myocardial @entity1 uptake from 14% to 22% in relation to the resting levels. In contrast, mean delta-values of metabolites ranged from 5% to 136% in relation to the respective A-V differences during the study. The greatest variation occurred during pacing and of all the metabolites @entity5 exchange varied most. A spontaneous variation in the degree of ischaemia during repeat stress tests might be the major reason for the metabolite variability. Changes in CSBF, however, tended to correlate inversely to the delta-aortocoronary sinus differences of substrates during pacing. Precision of chemical analysis and blood sampling technique were of minor importance for the variability. Since @entity5 exchange varied most, the study suggests that additional measurements should be made of more metabolites when assessing the efficacy of therapy by means of myocardial metabolism.

title: Reproducibility of coronary haemodynamics and cardiac metabolism during pacing-induced XXXX .

answer: @entity6


abstract: The results of foot lymphography in 295 @entity0 with @entity3 observed from 1968 to 1978 at two institutions are reported. One hundred and eighty-two were new cases, 61 were recurrences, and 52 were @entity0 who underwent restaging diagnostic procedures without clinical evidence of disease. The incidence of lymphatic spread was correlated with the clinical stage, the pathologic stage, and the extent of recurrent disease. In fact, in the 182 new cases, at clinical stage, the pathologic stage, lymphography was positive in 8.9% of @entity0 at Stage I, 28.6% at Stage II, 57.1% at Stage III, and 66.6% at Stage IV disease; at pathological stage, lymphography was positive in 8% of @entity0 at Stage I, 14.8% at Stage II, 39.3% at Stage II, and 53.3% at Stage IV disease. There was lymph node involvement in 47.5% of the 61 pretreated @entity0 . Finally, in 52 pretreated @entity0 with no evidence of disease, the incidence of lymph node involvement was 7.7%. In new cases, @entity1 were found only in the pelvic nodes in 56.2% of the @entity0 and only in the para-aortic nodes in 9.5%; in 34.3%, both chains were simultaneously involved. The five-year survival rate for @entity0 at Stage I, II, and @entity2 with positive lymphography was 35% as compared with 73% for negative cases. In @entity0 at Stage I and II, the difference of survival was equal to 24%. The reliability of the results is confirmed by the concordance with the data of the literature on histologic involvement, by the first radiologic-pathologic comparison, and by the clinical course of the positive cases. Lymphography is of unquestionable value for an appropriate staging and for a correct plan of treatment.

title: Are retroperitoneal lymph node XXXX a major problem in @entity3 ? Diagnostic and prognostic assessment with lymphography.

answer: @entity1


abstract: The results of foot lymphography in 295 @entity0 with @entity3 observed from 1968 to 1978 at two institutions are reported. One hundred and eighty-two were new cases, 61 were recurrences, and 52 were @entity0 who underwent restaging diagnostic procedures without clinical evidence of disease. The incidence of lymphatic spread was correlated with the clinical stage, the pathologic stage, and the extent of recurrent disease. In fact, in the 182 new cases, at clinical stage, the pathologic stage, lymphography was positive in 8.9% of @entity0 at Stage I, 28.6% at Stage II, 57.1% at Stage III, and 66.6% at Stage IV disease; at pathological stage, lymphography was positive in 8% of @entity0 at Stage I, 14.8% at Stage II, 39.3% at Stage II, and 53.3% at Stage IV disease. There was lymph node involvement in 47.5% of the 61 pretreated @entity0 . Finally, in 52 pretreated @entity0 with no evidence of disease, the incidence of lymph node involvement was 7.7%. In new cases, @entity1 were found only in the pelvic nodes in 56.2% of the @entity0 and only in the para-aortic nodes in 9.5%; in 34.3%, both chains were simultaneously involved. The five-year survival rate for @entity0 at Stage I, II, and @entity2 with positive lymphography was 35% as compared with 73% for negative cases. In @entity0 at Stage I and II, the difference of survival was equal to 24%. The reliability of the results is confirmed by the concordance with the data of the literature on histologic involvement, by the first radiologic-pathologic comparison, and by the clinical course of the positive cases. Lymphography is of unquestionable value for an appropriate staging and for a correct plan of treatment.

title: Are retroperitoneal lymph node @entity1 a major problem in XXXX ? Diagnostic and prognostic assessment with lymphography.

answer: @entity3


abstract: BACKGROUND: Grass @entity2 ( @entity4 .) is a valuable resource for potentially durable partial resistance to rust. To gain insight into the resistance mechanism and identify potential resistance genes, we generated the first comprehensive transcriptome assemblies from control and Uromyces pisi inoculated leafs of a susceptible and a partially rust-resistant grass @entity2 genotype by RNA-seq. RESULTS: 134,914 contigs, shared by both libraries, were used to analyse their differential expression in response to @entity0 . Functional annotation grouped 60.4% of the contigs present in plant databases (37.8% of total) to 33 main functional categories, being "protein", "RNA", "signalling", "transport" and "stress" the most represented. Transcription profiles revealed considerable differences in regulation of major phytohormone signalling pathways: whereas Salicylic and Abscisic Acid pathways were up-regulated in the resistant genotype, @entity3 and @entity1 pathways were down-regulated in the susceptible one. As potential Resistance-genes we identified a mildew resistance locus O (MLO)-like gene, and MLO-related transcripts. Also, several pathogenesis-related genes were up-regulated in the resistant and exclusively down regulated in the susceptible genotype. Pathogen effectors identified in both inoculated libraries, as e.g. the rust Rtp1 transcript, may be responsible for the down-regulation of defence-related transcripts. The two genotypes contained 4,892 polymorphic contigs with SNPs unevenly distributed between different functional categories. Protein degradation (29.7%) and signalling receptor kinases (8.2%) were the most diverged, illustrating evolutionary adaptation of grass @entity2 to the host/pathogens arms race. CONCLUSIONS: The vast array of novel, resistance-related genomic information we present here provides a highly valuable resource for future smart breeding approaches in this hitherto under-researched, valuable legume crop.

title: Allelic diversity in the transcriptomes of contrasting rust-infected genotypes of XXXX , a lasting resource for smart breeding.

answer: @entity4


abstract: BACKGROUND: The hemolytic activity of inhaled particles such as @entity5 has been widely investigated in the past and represents a usual toxicological endpoint to characterize particle reactivity despite the fact that red blood cells (RBCs) are not involved in the pathogenesis of @entity1 or @entity2 caused by some inhaled particles. The inflammatory process induced by @entity5 starts with the activation of the inflammasome, which leads to the release of mature @entity3 . One of the upstream mechanisms causing activation of the inflammasome is the labilization of the phagolysosomal membrane after particle phagocytosis. Considering RBC lysis as a model of membrane damage, we evaluated the relationship between hemolytic activity and inflammasome-dependent release of @entity3 for a panel of selected @entity5 particles, in search of the toxicological significance of the hemolytic activity of an inhaled particle. METHODS: Well-characterized @entity5 particles, including four quartz samples and a vitreous @entity5 , with different surface properties and hemolytic potential were tested for their capacity to induce inflammasome-dependent release of @entity3 in LPS-primed primary @entity0 peritoneal macrophages by ELISA and Western blot analysis. The mechanisms of @entity3 maturation and release were clarified by using ASC-deficient cells and inhibitors of phagocytosis and @entity6 . RESULTS: The @entity5 samples induced dose-dependent @entity4 and @entity3 release of different amplitudes. A significant correlation between @entity3 release and hemolytic activity was evidenced (r   =   0.827) by linear regression analysis. @entity3 release was completely abolished in ASC-deficient cells and reduced by inhibitors, confirming the involvement of the inflammasome and the requirement of phagocytosis and @entity6 for activation. CONCLUSIONS: The same physico-chemical properties of @entity5 particles which are relevant for the lysis of the RBC membrane also appear implicated in the labilization of the phagolysosome, leading to inflammasome activation and release of the pro-inflammatory cytokine @entity3 . These findings strengthen the relevance of the @entity4 assay to predict the pro-inflammatory activity of @entity5 dusts.

title: Why does the hemolytic activity of XXXX predict its pro-inflammatory activity?

answer: @entity5


abstract: UNASSIGNED: BackgroundMammography screen-detected @entity0 have a better prognosis than predicted from established prognostic markers. A search for additional features that are characteristic for these @entity2 and their prognosis is needed to reduce overtreatment, a recognized challenge in @entity0 @entity1 management today. Here, we have investigated the occurrence and importance of @entity2 @entity5 .MethodsWe performed a population based retrospective study of @entity0 detected in the Norwegian Breast Cancer Screening Programme in Vestfold County during 2004  2009. In total, 197 invasive screen-detected @entity2 and 75 @entity2 in @entity1 aged 50  69 years were compared with regard to standard clinico-pathological parameters and @entity2 shape, as well as ER, PR, @entity4 and Ki67 expression. In particular, the presence of elastotic @entity2 was graded on a 4-tiered scale (score 0  3).ResultsScreen-detected @entity2 had a significantly higher content of stromal @entity5 than @entity2 (p  <  0.001). High content of @entity5 (score 3) correlated strongly with stellate @entity2 shape, low histological grade, and ER+/ @entity4 - status. Further, high @entity5 score was significantly associated with lower Ki67 expression. In survival analyses, cases with high @entity5 demonstrated increased recurrence free (p  =  0.03) and disease-specific survival (p  =  0.11) compared to cases with @entity3 .ConclusionThere is a strong correlation between the presence of @entity2 shape and mammography detection of @entity0 . To our knowledge, this is the first time @entity5 has been studied in relation to @entity0 detection method. Presence of @entity5 is associated with low @entity2 cell proliferation (Ki67) and a good prognosis.Virtual SlidesThe virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/13000_2014_230.

title: XXXX stromal @entity5 is associated with mammography screening detection, low Ki67 expression and favourable prognosis in a population-based study.

answer: @entity0


abstract: UNASSIGNED: BackgroundMammography screen-detected @entity0 have a better prognosis than predicted from established prognostic markers. A search for additional features that are characteristic for these @entity2 and their prognosis is needed to reduce overtreatment, a recognized challenge in @entity0 @entity1 management today. Here, we have investigated the occurrence and importance of @entity2 @entity5 .MethodsWe performed a population based retrospective study of @entity0 detected in the Norwegian Breast Cancer Screening Programme in Vestfold County during 2004  2009. In total, 197 invasive screen-detected @entity2 and 75 @entity2 in @entity1 aged 50  69 years were compared with regard to standard clinico-pathological parameters and @entity2 shape, as well as ER, PR, @entity4 and Ki67 expression. In particular, the presence of elastotic @entity2 was graded on a 4-tiered scale (score 0  3).ResultsScreen-detected @entity2 had a significantly higher content of stromal @entity5 than @entity2 (p  <  0.001). High content of @entity5 (score 3) correlated strongly with stellate @entity2 shape, low histological grade, and ER+/ @entity4 - status. Further, high @entity5 score was significantly associated with lower Ki67 expression. In survival analyses, cases with high @entity5 demonstrated increased recurrence free (p  =  0.03) and disease-specific survival (p  =  0.11) compared to cases with @entity3 .ConclusionThere is a strong correlation between the presence of @entity2 shape and mammography detection of @entity0 . To our knowledge, this is the first time @entity5 has been studied in relation to @entity0 detection method. Presence of @entity5 is associated with low @entity2 cell proliferation (Ki67) and a good prognosis.Virtual SlidesThe virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/13000_2014_230.

title: @entity0 stromal XXXX is associated with mammography screening detection, low Ki67 expression and favourable prognosis in a population-based study.

answer: @entity5


abstract: UNASSIGNED: OBJECT The authors prospectively analyzed 2 microscope-integrated videoangiography techniques using intravenous @entity4 (ICG) and @entity3 for assessment of cerebral @entity2 and adjacent vessel patency. METHODS The authors prospectively enrolled 22 @entity0 who underwent clip ligation of their @entity2 and used intraoperative videoangiography to assess obliteration of the aneurysmal sac and patency of the adjacent branching and perforating arteries. @entity0 underwent ICG videoangiography (ICG-VA) and the newly developed @entity3 videoangiography (FL-VA) using microscope-integrated fluorescence modules. Two independent observers compared the videoangiography recordings for value and quality to assess @entity2 exclusion and the patency of adjacent arteries. RESULTS All 22 @entity0 first underwent FL-VA and then ICG-VA after clip application. In 7 cases (32%), FL-VA provided superior detail to assess perforating arteries (4 cases), distal branches (2 cases), and both (1 case); such detail was not readily available on ICG-VA. In 1 @entity0 , ICG-VA offered better visualization of posterior communicating @entity1 than FL-VA because of staining artifact on the @entity2 dome from the adjacent tentorium. In 2 @entity0 , FL-VA offered the needed advantage of real-time manipulation of the vessels and flow assessment by visualization through the operating microscope oculars. In 2 other cases, ICG-VA was more practical for repeat usage because of its more efficient clearance from the intravascular space. The ICG-VA image quality was often degraded at higher magnification in deep operative fields, partly due to chromatic aberration. Both ICG-VA and FL-VA afforded restricted views of vasculature based on the angle of surgical approach and obscuration by @entity5 , @entity2 , or brain tissue. CONCLUSIONS Compared with ICG-VA, FL-VA can potentially provide an improved visualization of vasculature at high magnification in deep surgical fields. ICG-VA is more effective for repeated use during clip repositioning due to ICG's minimal vascular wall extravasation. Therefore, in certain cases, FL-VA may offer some advantages and play a complementary role along with ICG-VA in intraoperative fluorescence evaluation during microsurgical management of @entity2 .

title: A prospective comparative study of microscope-integrated intraoperative XXXX and indocyanine videoangiography for clip ligation of complex cerebral aneurysms.

answer: @entity3


abstract: BACKGROUND: Thai traditional remedy called Kabpi (KP) has long been usedfor oral and @entity0 . It composed with four herbs Syzygium aromaticum (L.) Merr etPerry, Nigella sativa L., Limonia acidissima L. andAchasma sphaerocephalum Holtt. OBJECTIVE: To investigate antimicrobial activity ofKP remedy extracts and its plant components. MATERIAL AND METHOD: The extract procedures were maceration method with 95% @entity2 , 50% @entity2 and dried by evaporator and boiling in water, filtrated dried by lyophilizer The residue from the maceration in 95% @entity2 and 50% @entity2 were boiled in water and dried by lyophilizer In the preliminary studied, all extracts were evaluated antimicrobial activity by disc diffusion method. All extracts were tested against one type of gram positive bacteria @entity1 (ATCC 25923) and one type ofyeast @entity3 (ATCC 90028). The active plant extracts were diluted to determine the minimum inhibitory concentration (MIC) values by microtiter plate-based assay. RESULTS: The 95% @entity2 extract of KP remedy showed antimicrobial activity against @entity1 (ATCC 25923) and @entity3 (ATCC 90028) (MIC = 0.625, 0.625 mg/ml, respectively). The zone of inhibition ofall extracts were in the range of 7.33 to 23.33 mm. The 95% @entity2 extract ofAchasma sphaerocephalum Holtt. showed the highest inhibition zone against @entity1 21.00 mm (MIC = 0.625 mg/ml). The 95% @entity2 extract ofSyzygium aromaticum (L.) Merr etPerry exhibited the best antimicrobial activity against @entity3 the inhibition zone with inhibition zone of23.33 mm (MIC = 0.156 mg/ml). CONCLUSION: The present study demonstrated that the extracts ofKP remedy and its plant components had an antimicrobial effect against oral and @entity0 such as @entity1 and @entity3 . These results support using this remedy of Thai traditional medicine called Kabpifor oral and @entity0 .

title: Antimicrobial activity of extracts from a Thai traditional remedy called Kabpi for oral and XXXX and its plant components.

answer: @entity0


abstract: OBJECTIVE: to define the optimal approach for self-expanding metal stents (SEMS) installing in the cervical esophagus in cases of @entity1 and to select the optimal types of stents for this @entity1 location. MATERIALS: From 2004 to 2013 in P.A. Herzen Moscow Cancer Research Institute in 24 @entity0 with cervical @entity1 @entity3 endoscopic stenting was performed. 70% of installed stents were Choo Cervical (M.I. Tech, Korea), 13%--unspecialized Choo and Hanaro stents (M.I. Tech, Korea), and 17%--Gianturco-Z stents (Wilson-Cook, Ireland). Main contraindication for cervical esophagus stenting was location of the @entity1 margin less than 1 cm from the upper esophageal sphincter. In 21% of cases, endoscopic stenting was performed under combined @entity5 - and endoscopic guidance, in 79%-- using only endoscopic approach. RESULTS: Technical success of stent placement was achieved in all @entity0 ; SEMS was installed at the previously defined level. The accuracy of stenting was not depended from the type of guidance procedure. The most intensive @entity2 was observed in cases with "not specialized" stents with diameter of 18, 20 or 22 mm. Average @entity2 level in such @entity0 was 4.54 points (VAS). In the subgroup with "cervical" stents average @entity2 intensity was not exceed 3 points. @entity4 syndrome lasts lifelong in 17% of @entity0 . CONCLUSION: The procedure of SEMS positioning under endoscopic guidance with individual selection of stent type allows restoring oral nutrition in @entity0 with severe @entity1 @entity3 of the cervical esophagus.

title: [Endoscopic stenting of XXXX in the cervical esophagus].

answer: @entity1


abstract: AIM: To investigate the demographic and clinical characteristics of @entity0 with @entity3 ( @entity3 ) and @entity3 ( @entity3 ), regions of their residence, the specific features of diagnosis and drug therapy, and the @entity0 ' survival within the framework of a multicenter open-label prospective study. SUBJECTS AND METHODS: The study enrolled @entity0 over 18 years of age with @entity3 classified as Group 1 ( @entity3 ) and Group 4 ( @entity3 ). The follow-up was made in 9 expert centers of Russia on January 1 to February 28, 2014. The data of @entity0 with @entity3 and @entity3 were electronically entered at the register website: www.pul-hyp.medibase.ru. RESULTS: The study included 242 @entity0 (183 @entity0 and 59 @entity0 ) from 44 regions of the Russian Federation. @entity3 of different etiologies was present in 79.3%, including 43.8% with idiopathic @entity3 , 28.5% with @entity4 -associated @entity3 , 6.2% with diffuse connective tissue-associated @entity3 , 0.8% with hereditary @entity3 ; 20.7% were diagnosed with @entity3 . The @entity0 ' mean age at the inclusion in the register was 43.2    15.8 years; the median @entity3 duration was 4.4 years (1.4 to 10.6%). The distance covered during a 6-minute walk test was 395.2?111.1 m; the Borg dyspnea index was 3.4    1.4 scores and the functional class was 2.5    0.8. After right cardiac catheterization, the mean pulmonary artery pressure was 53.1    19.5 mm Hg; cardiac output, 3.8    1.2 l/ min; cardiac index, 2.1    0.6 l/min/m2; pulmonary vascular resistance, 1105    677.6 dyn  sec/cm5. A positive acute pharmacological test was seen in 16.3% of the @entity0 . The most common comorbidity was erosive @entity6 of the gastrointestinal tract (23.5%), @entity2 (16.9%), and @entity1 (16.5%). 66% of the @entity0 received @entity3 -specific therapy: @entity7 (51.6%), @entity8 (20.9%), or iloprost (7%); 7.4% of the @entity0 were observed within the framework of clinical trials, 17.7% received combined therapy for @entity3 : 16.3 and 1.4% had dual- or triple-component therapy, respectively; 55.8% of the @entity0 took @entity5 antagonists, 61.4% had diuretics, 85.6% had antithrombotic drugs. The survival rates were 98% in the first year of the follow-up and 90.1% by the end of 2013. CONCLUSION: The formation of a national register of @entity0 with @entity3 and @entity3 makes it possible to introduce current approaches to diagnosing and treating the @entity0 of this category and to evaluate the efficiency and quality of rendered medical care and will contribute to the estimation of required health care volumes and the expenditure of public health resources.

title: [Pulmonary XXXX in Russia: the first results of the national register].

answer: @entity2


abstract: From the trypsinized skin of a @entity1 embryo, a fibroblastic cell line has been obtained ( @entity3 cells). The primary seed lot has been established at 11th passage. The tests for tumorigenicity on nu/nu @entity0 were negative (10(4) cell/animal) at passage level 11th and 50th. Cell growth and morphology were not altered when 100 passages were performed. @entity3 cells were tested for their susceptibility to @entity4 . The production of virus on @entity3 cells was investigated after infection by the P.V. @entity4 adapted to several cell types ( @entity2 fetal kidney, Vero and BHK cells). For the evaluation of an experimental rabies vaccine produced with this substrate, @entity3 cells were compared to Vero cells. The synthesis of glycoprotein (EIA) and the immunogenicity (NIH test) were similar for the vaccines obtained with both cell systems. @entity3 cells could therefore be an alternative to Vero cells for the production of a cell culture inactivated rabies vaccine.

title: A rabies vaccine produced in a non-tumorigenic XXXX cell line.

answer: @entity1


abstract: The evaluation of the risk of complications and @entity6 from cardiovascular causes is conducted in all @entity0 with @entity11 ( @entity11 ) using a variety of methods. The assessment of the risk of @entity4 , including also @entity6 , the cause of which are @entity4 , is a very important and essential part of clinical evaluation. Moreover, all @entity0 with @entity11 are assessed as regards the risk of complications and in-hospital mortality and the short- and long-term @entity0 outcomes. Recently, in the prognostic assessment of @entity11 @entity0 attention has been paid to @entity12 , @entity8 , and decreased GFR, which might worsen the prognosis. @entity12 on admission and especially its occurrence and persistence during hospitalization speak for particularly poor prognosis. Furthermore, the annual and long-term mortality rate is observed to increase with the higher HbA1c level, regardless of the @entity7 concentration on admission to hospital. Increased risk of the occurrence of @entity4 is observed with the intensity of the @entity3 which is reflected, among others, in elevated number of peripheral blood leukocytes. Attention is drawn to the higher rate of complications in @entity0 with @entity8 . The correlation between the increase in leukocyte count and all-cause mortality is statistically significant. A higher risk of non- fatal @entity9 is also observed with the @entity8 . Neutrophils, which are the main pool of white blood cells, and whose activation is observed during PCI, may play a role in these unfavorable phenomena. This activation results in increased production of @entity2 free radicals by these cells, intensification of adhesion and aggregation. A number of studies point to the cardioprotective mechanism of action of statins (anti-inflammatory and anti- @entity10 ) in @entity0 with @entity11 . The use of leukocyte reduction filters in @entity0 during CABG may be one of the methods limiting the impact of @entity8 on @entity4 in @entity0 with @entity11 . @entity5 is a strong and independent predictor of mortality in @entity0 with @entity11 . Contrast-induced @entity1 is a complication following coronarography which is performed in @entity0 with @entity11 for diagnostic and therapeutic purposes. @entity12 also has an adverse effect on this complication. The prevention of contrast-induced @entity1 includes the use of statins prior to PCI.

title: [The prognostic value of XXXX , @entity8 and decreased glomerular filtration rate in @entity11 --pharmacological protection capabilities].

answer: @entity12


abstract: The evaluation of the risk of complications and @entity6 from cardiovascular causes is conducted in all @entity0 with @entity11 ( @entity11 ) using a variety of methods. The assessment of the risk of @entity4 , including also @entity6 , the cause of which are @entity4 , is a very important and essential part of clinical evaluation. Moreover, all @entity0 with @entity11 are assessed as regards the risk of complications and in-hospital mortality and the short- and long-term @entity0 outcomes. Recently, in the prognostic assessment of @entity11 @entity0 attention has been paid to @entity12 , @entity8 , and decreased GFR, which might worsen the prognosis. @entity12 on admission and especially its occurrence and persistence during hospitalization speak for particularly poor prognosis. Furthermore, the annual and long-term mortality rate is observed to increase with the higher HbA1c level, regardless of the @entity7 concentration on admission to hospital. Increased risk of the occurrence of @entity4 is observed with the intensity of the @entity3 which is reflected, among others, in elevated number of peripheral blood leukocytes. Attention is drawn to the higher rate of complications in @entity0 with @entity8 . The correlation between the increase in leukocyte count and all-cause mortality is statistically significant. A higher risk of non- fatal @entity9 is also observed with the @entity8 . Neutrophils, which are the main pool of white blood cells, and whose activation is observed during PCI, may play a role in these unfavorable phenomena. This activation results in increased production of @entity2 free radicals by these cells, intensification of adhesion and aggregation. A number of studies point to the cardioprotective mechanism of action of statins (anti-inflammatory and anti- @entity10 ) in @entity0 with @entity11 . The use of leukocyte reduction filters in @entity0 during CABG may be one of the methods limiting the impact of @entity8 on @entity4 in @entity0 with @entity11 . @entity5 is a strong and independent predictor of mortality in @entity0 with @entity11 . Contrast-induced @entity1 is a complication following coronarography which is performed in @entity0 with @entity11 for diagnostic and therapeutic purposes. @entity12 also has an adverse effect on this complication. The prevention of contrast-induced @entity1 includes the use of statins prior to PCI.

title: [The prognostic value of @entity12 , XXXX and decreased glomerular filtration rate in @entity11 --pharmacological protection capabilities].

answer: @entity8


abstract: The evaluation of the risk of complications and @entity6 from cardiovascular causes is conducted in all @entity0 with @entity11 ( @entity11 ) using a variety of methods. The assessment of the risk of @entity4 , including also @entity6 , the cause of which are @entity4 , is a very important and essential part of clinical evaluation. Moreover, all @entity0 with @entity11 are assessed as regards the risk of complications and in-hospital mortality and the short- and long-term @entity0 outcomes. Recently, in the prognostic assessment of @entity11 @entity0 attention has been paid to @entity12 , @entity8 , and decreased GFR, which might worsen the prognosis. @entity12 on admission and especially its occurrence and persistence during hospitalization speak for particularly poor prognosis. Furthermore, the annual and long-term mortality rate is observed to increase with the higher HbA1c level, regardless of the @entity7 concentration on admission to hospital. Increased risk of the occurrence of @entity4 is observed with the intensity of the @entity3 which is reflected, among others, in elevated number of peripheral blood leukocytes. Attention is drawn to the higher rate of complications in @entity0 with @entity8 . The correlation between the increase in leukocyte count and all-cause mortality is statistically significant. A higher risk of non- fatal @entity9 is also observed with the @entity8 . Neutrophils, which are the main pool of white blood cells, and whose activation is observed during PCI, may play a role in these unfavorable phenomena. This activation results in increased production of @entity2 free radicals by these cells, intensification of adhesion and aggregation. A number of studies point to the cardioprotective mechanism of action of statins (anti-inflammatory and anti- @entity10 ) in @entity0 with @entity11 . The use of leukocyte reduction filters in @entity0 during CABG may be one of the methods limiting the impact of @entity8 on @entity4 in @entity0 with @entity11 . @entity5 is a strong and independent predictor of mortality in @entity0 with @entity11 . Contrast-induced @entity1 is a complication following coronarography which is performed in @entity0 with @entity11 for diagnostic and therapeutic purposes. @entity12 also has an adverse effect on this complication. The prevention of contrast-induced @entity1 includes the use of statins prior to PCI.

title: [The prognostic value of @entity12 , @entity8 and decreased glomerular filtration rate in XXXX --pharmacological protection capabilities].

answer: @entity11


abstract: Partial or complete absence of the thymus ( @entity5 , III-IV @entity5 ) is often associated with @entity6 or @entity3 of the parathyroid glands and, almost invariably, with @entity1 . The clinical and pathologcial findings in 10 cases proven at necropsy are presented. All @entity0 presented with cardiac symptoms and signs in the first weeks of life and, with one exception, all died of a cardiac cause. @entity1 were found in all 10 cases. Four had, in association with a @entity4 of the infundibular type, an interrupted @entity8 , which was left-sided in two and right-sided in two other cases. Four @entity0 had truncus arteriosus type I, in two of them associated with a right-sided @entity8 . Two @entity0 with @entity2 had a right-sided @entity8 . Only two of the 10 had a normally developed left @entity8 . Aberrant subclavian arteries were found in five cases. From our observations and a survey of the previously published @entity0 it appears that 90 per cent of the necropsy-proven cases of @entity5 have @entity1 and that 95 per cent of these malformations can be classified as @entity7 , truncus ateriosus, or @entity2 .

title: @entity1 in XXXX (congenital absence of hypoplasia of the thymus).

answer: @entity5


abstract: Partial or complete absence of the thymus ( @entity5 , III-IV @entity5 ) is often associated with @entity6 or @entity3 of the parathyroid glands and, almost invariably, with @entity1 . The clinical and pathologcial findings in 10 cases proven at necropsy are presented. All @entity0 presented with cardiac symptoms and signs in the first weeks of life and, with one exception, all died of a cardiac cause. @entity1 were found in all 10 cases. Four had, in association with a @entity4 of the infundibular type, an interrupted @entity8 , which was left-sided in two and right-sided in two other cases. Four @entity0 had truncus arteriosus type I, in two of them associated with a right-sided @entity8 . Two @entity0 with @entity2 had a right-sided @entity8 . Only two of the 10 had a normally developed left @entity8 . Aberrant subclavian arteries were found in five cases. From our observations and a survey of the previously published @entity0 it appears that 90 per cent of the necropsy-proven cases of @entity5 have @entity1 and that 95 per cent of these malformations can be classified as @entity7 , truncus ateriosus, or @entity2 .

title: XXXX in @entity5 (congenital absence of hypoplasia of the thymus).

answer: @entity1


abstract: @entity5 ( @entity5 ) is caused by autoantibodies against @entity4 ( @entity4 ). Immunosuppressive treatment (IST) results in remission of disease in 60% to 80% of @entity0 over a period of days to months. IST is associated with frequent adverse events, including infections as a leading cause of @entity1 . Predictors of time to remission could help guide IST intensity but have not been established. We analyzed prognostic factors in 102 prospectively enrolled @entity0 treated with a uniform IST protocol. Partial remission (PR; defined as no active @entity3 , @entity4 restored >50 IU/dL, hemostatic treatment stopped >24 hours) was achieved by 83% of @entity0 after a median of 31 days (range 7-362). @entity0 with baseline @entity4 <1 IU/dL achieved PR less often and later (77%, 43 days) than @entity0 with >= 1 IU/dL (89%, 24 days). After adjustment for other baseline characteristics, low @entity4 remained associated with a lower rate of PR (hazard ratio 0.52, 95% confidence interval 0.33-0.81, P < .01). In contrast, PR achieved on @entity2 alone within  <=21 days was more common in @entity0 with @entity4 >= 1 IU/dL and inhibitor concentration <20 BU/mL (odds ratio 11.2, P < .0001). Low @entity4 was also associated with a lower rate of complete remission and decreased survival. In conclusion, presenting @entity4 and inhibitor concentration are potentially useful to tailor IST in @entity5 .

title: Prognostic factors for remission of and survival in acquired hemophilia A ( XXXX ): results from the GTH-AH 01/2010 study.

answer: @entity5


abstract: Monocyte infiltration and activation of the coagulation system have been implicated in the pathophysiology of @entity4 . In this study, spontaneous procoagulant activity (PCA) was measured in circulating mononuclear cells to determine whether elevated PCA correlated with the presence of proliferative @entity4 in @entity0 with @entity5 ( @entity5 ). No increase in PCA was found in 20 @entity0 with @entity3 , 8 @entity0 with @entity4 without @entity5 , and 10 @entity0 undergoing abdominal surgical or orthopedic procedures as compared with 20 normal controls. In eight @entity0 with @entity5 but with no apparent @entity1 , PCA was not elevated above normal basal levels. Seven additional @entity0 with @entity5 who had only mesangial proliferation on biopsy also had no increase in PCA. In contrast, eight @entity0 with focal or diffuse proliferative @entity7 , and one @entity0 with @entity6 who ultimately developed a @entity2 , had a marked increase in PCA with greater than 100 times the base-line levels. The activity was shown to originate in the monocyte fraction of the mononuclear cells and was shown to be capable of cleaving prothrombin directly. The prothrombinase activity was not @entity8 , because it was not neutralized by anti-Factor X serum and was not inhibited by an established panel of @entity8 inhibitors. Monocyte plasminogen activator determinations did not correlate with @entity1 activity. We conclude that monocyte procoagulant activity, a direct prothrombinase, seems to correlate with endocapillary proliferation in @entity7 and could be a mediator of tissue injury.

title: Monocyte procoagulant activity in XXXX associated with @entity5 .

answer: @entity4


abstract: Monocyte infiltration and activation of the coagulation system have been implicated in the pathophysiology of @entity4 . In this study, spontaneous procoagulant activity (PCA) was measured in circulating mononuclear cells to determine whether elevated PCA correlated with the presence of proliferative @entity4 in @entity0 with @entity5 ( @entity5 ). No increase in PCA was found in 20 @entity0 with @entity3 , 8 @entity0 with @entity4 without @entity5 , and 10 @entity0 undergoing abdominal surgical or orthopedic procedures as compared with 20 normal controls. In eight @entity0 with @entity5 but with no apparent @entity1 , PCA was not elevated above normal basal levels. Seven additional @entity0 with @entity5 who had only mesangial proliferation on biopsy also had no increase in PCA. In contrast, eight @entity0 with focal or diffuse proliferative @entity7 , and one @entity0 with @entity6 who ultimately developed a @entity2 , had a marked increase in PCA with greater than 100 times the base-line levels. The activity was shown to originate in the monocyte fraction of the mononuclear cells and was shown to be capable of cleaving prothrombin directly. The prothrombinase activity was not @entity8 , because it was not neutralized by anti-Factor X serum and was not inhibited by an established panel of @entity8 inhibitors. Monocyte plasminogen activator determinations did not correlate with @entity1 activity. We conclude that monocyte procoagulant activity, a direct prothrombinase, seems to correlate with endocapillary proliferation in @entity7 and could be a mediator of tissue injury.

title: Monocyte procoagulant activity in @entity4 associated with XXXX .

answer: @entity5


abstract: UNASSIGNED: The aim of this study was to evaluate the capability of thromboelastometry (ROTEM) and @entity2 generation assay (TGA) to monitor the treatment response of bypassing agent (BPA) therapy and to study whether one method is superior to another. In a prospective crossover study @entity1 @entity0 with high titre inhibitors were included to receive a dose of 75  U  kg(-1) activated prothrombin complex concentrates (aPCC) intravenously. Blood sampling was performed at baseline, 15, 30  min, 1, 2, 3 and 4  h post-infusion for TGA and ROTEM analysis. After a washout period of 14  days the subjects received recombinant FVIIa (rFVIIa) at a dose of 90   g  kg(-1) and similar blood sampling was performed. Healthy subjects were used as controls. Six @entity1 @entity0 with inhibitors were included. We found that TGA parameters endogenous @entity2 potential (ETP) and peak @entity2 increased 2-3 folds from baseline 15-30  min after infusion. ROTEM parameters MaxVel and maximum clot firmness increased to a level comparable to that of healthy controls. An individual difference in response was observed for different parameters among @entity0 . ETP and peak @entity2 were almost two-fold greater following aPCC infusion compared to rFVIIa, whereas ROTEM parameters showed no difference in response between the two products. The study showed that ROTEM and TGA have a great potential to evaluate the effect of BPA in @entity1 @entity0 with inhibitors. TGA seemed to be more sensitive than ROTEM in reflecting the difference in treatment response between aPCC and rFVIIa. Additional prospective clinical studies are needed to clarify which assay and what parameters are clinically predictive.

title: Monitoring bypassing agent therapy - a prospective crossover study comparing thromboelastometry and XXXX generation assay.

answer: @entity2


abstract: BACKGROUND AND AIM: The feasibility of @entity3 , the synthetic infectious agent-free peptides, was tested in hemostasis of the @entity2 after endoscopic treatments of the @entity1 . METHODS: The @entity0 who underwent endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) were enrolled in the present study. The subject of hemostasis was the oozing after the EMR or ESD. The hemostatic effect, the secondary @entity2 from one postoperative day to the day before discharge and operability were studied. RESULTS: The hemostatic effects were assessed in 12 @entity0 . It was "remarkably effective" in 11 @entity0 and "effective" in 1 @entity0 . The operability was "very easy" in two @entity0 , "easy" in eight @entity0 and "acceptable" in two @entity0 . No secondary @entity2 was observed in all of 12 @entity0 . No adverse effect considered to be related to @entity3 was observed. CONCLUSION: It was shown that hemostasis using @entity3 was feasible after endoscopic treatments of the @entity1 without any technical trouble or adverse event.

title: Initial clinical trial of a novel hemostat, @entity3 , in the endoscopic treatments of the XXXX .

answer: @entity1


abstract: BACKGROUND AND AIM: The feasibility of @entity3 , the synthetic infectious agent-free peptides, was tested in hemostasis of the @entity2 after endoscopic treatments of the @entity1 . METHODS: The @entity0 who underwent endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) were enrolled in the present study. The subject of hemostasis was the oozing after the EMR or ESD. The hemostatic effect, the secondary @entity2 from one postoperative day to the day before discharge and operability were studied. RESULTS: The hemostatic effects were assessed in 12 @entity0 . It was "remarkably effective" in 11 @entity0 and "effective" in 1 @entity0 . The operability was "very easy" in two @entity0 , "easy" in eight @entity0 and "acceptable" in two @entity0 . No secondary @entity2 was observed in all of 12 @entity0 . No adverse effect considered to be related to @entity3 was observed. CONCLUSION: It was shown that hemostasis using @entity3 was feasible after endoscopic treatments of the @entity1 without any technical trouble or adverse event.

title: Initial clinical trial of a novel hemostat, XXXX , in the endoscopic treatments of the @entity1 .

answer: @entity3


abstract: AIMS: To describe the utilisation of antidiabetic agents , in terms of persistence and regimen change in the management of a cohort of newly treated @entity2 2 @entity1 @entity0 and to investigate associated socio-demographic and treatment factors. METHODS: A population-based retrospective cohort study was conducted using the national pharmacy claims database in Ireland. Subjects were analysed for persistence and regimen change. @entity3 proportional-hazards regression examined associations of socio-demographic and treatment factors on treatment patterns. Hazard ratios (HR) and 95% CIs are presented. RESULTS: 20947 subjects were identified in the study over a 2 year period. Most were initiated on @entity4 (76%) or sulphonylureas (22%) and 77% were persistent with therapy 12 months after initiation. The likelihood of non-persistence was significantly lower in the youngest (40-49) age groups (ref 60-69) (HR 1.62 [CI 1.42-1.84]) and those on sulphonylureas (HR 1.49 [1.36-1.64]). The likelihood of receiving a regimen change was significantly lower in the older (80+) age groups (HR 0.63 [0.56-0.71]), females (HR 0.91 [0.86-0.95], and those with pre-existing CVD (1 vs 0 CVD medicines) (HR 0.82 [0.74-0.90]), and higher in those on sulphonylureas (HR 1.83 [1.73-1.94]) CONCLUSIONS: Type of treatment, pre-existing CVD and demographic factors are shown to be associated with the observed treatment patterns. Guideline recommended agents were widely used on treatment initiation though a substantial minority were not initiated on the recommended first line agent. Use of guideline recommended agents was not as evident during treatment progression. Further optimisation of initial and subsequent antidiabetic agent prescribing may be possible.

title: Initial therapy, persistence and regimen change in a cohort of newly treated XXXX 2 @entity1 @entity0 .

answer: @entity2


abstract: AIMS: To describe the utilisation of antidiabetic agents , in terms of persistence and regimen change in the management of a cohort of newly treated @entity2 2 @entity1 @entity0 and to investigate associated socio-demographic and treatment factors. METHODS: A population-based retrospective cohort study was conducted using the national pharmacy claims database in Ireland. Subjects were analysed for persistence and regimen change. @entity3 proportional-hazards regression examined associations of socio-demographic and treatment factors on treatment patterns. Hazard ratios (HR) and 95% CIs are presented. RESULTS: 20947 subjects were identified in the study over a 2 year period. Most were initiated on @entity4 (76%) or sulphonylureas (22%) and 77% were persistent with therapy 12 months after initiation. The likelihood of non-persistence was significantly lower in the youngest (40-49) age groups (ref 60-69) (HR 1.62 [CI 1.42-1.84]) and those on sulphonylureas (HR 1.49 [1.36-1.64]). The likelihood of receiving a regimen change was significantly lower in the older (80+) age groups (HR 0.63 [0.56-0.71]), females (HR 0.91 [0.86-0.95], and those with pre-existing CVD (1 vs 0 CVD medicines) (HR 0.82 [0.74-0.90]), and higher in those on sulphonylureas (HR 1.83 [1.73-1.94]) CONCLUSIONS: Type of treatment, pre-existing CVD and demographic factors are shown to be associated with the observed treatment patterns. Guideline recommended agents were widely used on treatment initiation though a substantial minority were not initiated on the recommended first line agent. Use of guideline recommended agents was not as evident during treatment progression. Further optimisation of initial and subsequent antidiabetic agent prescribing may be possible.

title: Initial therapy, persistence and regimen change in a cohort of newly treated @entity2 2 XXXX @entity0 .

answer: @entity1


abstract: AIMS: To describe the utilisation of antidiabetic agents , in terms of persistence and regimen change in the management of a cohort of newly treated @entity2 2 @entity1 @entity0 and to investigate associated socio-demographic and treatment factors. METHODS: A population-based retrospective cohort study was conducted using the national pharmacy claims database in Ireland. Subjects were analysed for persistence and regimen change. @entity3 proportional-hazards regression examined associations of socio-demographic and treatment factors on treatment patterns. Hazard ratios (HR) and 95% CIs are presented. RESULTS: 20947 subjects were identified in the study over a 2 year period. Most were initiated on @entity4 (76%) or sulphonylureas (22%) and 77% were persistent with therapy 12 months after initiation. The likelihood of non-persistence was significantly lower in the youngest (40-49) age groups (ref 60-69) (HR 1.62 [CI 1.42-1.84]) and those on sulphonylureas (HR 1.49 [1.36-1.64]). The likelihood of receiving a regimen change was significantly lower in the older (80+) age groups (HR 0.63 [0.56-0.71]), females (HR 0.91 [0.86-0.95], and those with pre-existing CVD (1 vs 0 CVD medicines) (HR 0.82 [0.74-0.90]), and higher in those on sulphonylureas (HR 1.83 [1.73-1.94]) CONCLUSIONS: Type of treatment, pre-existing CVD and demographic factors are shown to be associated with the observed treatment patterns. Guideline recommended agents were widely used on treatment initiation though a substantial minority were not initiated on the recommended first line agent. Use of guideline recommended agents was not as evident during treatment progression. Further optimisation of initial and subsequent antidiabetic agent prescribing may be possible.

title: Initial therapy, persistence and regimen change in a cohort of newly treated @entity2 2 @entity1 XXXX .

answer: @entity0


abstract: UNASSIGNED: @entity4 is a rare @entity1 in the anterior skull base with frequent intracranial extension. Combined management between otolaryngologist and neurosurgeons are @entity1 resection and to minimize the complications of treatment Endoscopic resection of the nasal part of the @entity1 is not only for aesthetic consideration. The superior illumination and visualization offered by the endoscopy enables the surgeon to adequately resect the @entity1 especially in the posterior ethimoid and sphenoid sinuses. @entity2 allows the surgeon to better appreciate the intracranial extent of @entity1 and to ensure an adequate dura resection margin. In addition, a craniotomy approach allows a water-tight dura closure with stitches and reinforcement by a vascularized galeal-pericranial flap, minimizing post operative @entity5 . In our case series of 14 @entity0 spanning 14 years, only one @entity0 died of disease. The ten-year overall survival is 93%. Seven @entity0 have local or regional recurrence; all except one was salvaged with additional surgery and/or radiotherapy. The survival results are comparable to open craniofacial resection. Our results showed that @entity3 (Kadish stage C) increased the risk for disease recurrence. Loco-regional regional recurrence can be salvaged with addition surgery and/or radiotherapy and can achieve long-term survival. This article is protected by copyright. All rights reserved.

title: Long-term results of endoscopic assisted cranionasal resection for XXXX - single centre experience of 14 @entity0 .

answer: @entity4


abstract: UNASSIGNED: @entity4 is a rare @entity1 in the anterior skull base with frequent intracranial extension. Combined management between otolaryngologist and neurosurgeons are @entity1 resection and to minimize the complications of treatment Endoscopic resection of the nasal part of the @entity1 is not only for aesthetic consideration. The superior illumination and visualization offered by the endoscopy enables the surgeon to adequately resect the @entity1 especially in the posterior ethimoid and sphenoid sinuses. @entity2 allows the surgeon to better appreciate the intracranial extent of @entity1 and to ensure an adequate dura resection margin. In addition, a craniotomy approach allows a water-tight dura closure with stitches and reinforcement by a vascularized galeal-pericranial flap, minimizing post operative @entity5 . In our case series of 14 @entity0 spanning 14 years, only one @entity0 died of disease. The ten-year overall survival is 93%. Seven @entity0 have local or regional recurrence; all except one was salvaged with additional surgery and/or radiotherapy. The survival results are comparable to open craniofacial resection. Our results showed that @entity3 (Kadish stage C) increased the risk for disease recurrence. Loco-regional regional recurrence can be salvaged with addition surgery and/or radiotherapy and can achieve long-term survival. This article is protected by copyright. All rights reserved.

title: Long-term results of endoscopic assisted cranionasal resection for @entity4 - single centre experience of 14 XXXX .

answer: @entity0


abstract: The present study was performed on conscious, chronically instrumented @entity1 , which underwent selective blockade of sympathetic adrenergic and vagal outflows. Excitements were performed on these animals in normal states (N), after chronic treatment with @entity4 , for sympathetic blockade (SB), after cold vagal blockade (VB), and after combined sympathetic and vagal blockade (SB + VB). Heart rate and arterial blood pressure were monitored in all the experiments, while a group of @entity1 was also tested with an electromagnetic flowmeter on the superior mesenteric artery. The role of the sympathetic and parasympathetic controls in the defence reaction was assumed from comparison of experiments performed in the presence or in the absence of each (or both) autonomic component(s). In the SB + VB condition, excitement was followed by @entity2 , without changes in heart rate. In VB experiments, a brief and transient @entity2 appeared, followed by gradually developed @entity0 , while heart rate progressively rose in about 5 s; there was no sudden increase in mesenteric vascular resistance, which contrasted with the very marked reaction in N experiments. Under vagal control alone (SB), the stimulus elicited prompt @entity3 and @entity0 , followed by a period of moderately reduced blood pressure. We conclude that, while the defence reaction leads to a @entity2 , in the absence of compensatory mechanisms, both branches of the autonomic nervous system play a protective role against @entity2 . In addition, the modulation of the vagal outflow, leading to sudden changes in the heart performance, seems to be responsible for the initiation of the overall haemodynamic adjustments following excitements. The possibility that withdrawal of the parasympathetic outflow to the heart may raise arterial blood pressure was verified in a special experiment in which artificial vagal stimulation in a conscious (vagal blocked) @entity1 , was turned off for brief periods, before and after @entity4 . This led to changes in blood pressure and heart rate very similar to those seen at the onset of the defence reaction, both in N and SB conditions.

title: Role of the autonomic nervous system in the control of heart rate and blood pressure in the defence reaction in conscious XXXX .

answer: @entity1


abstract: The case is described of a 14-year-old @entity0 who presented with a 6-week history of fatigue, severe @entity4 (15 kg) and @entity12 . On admission he was in non-oliguric @entity1 (serum @entity6 1360 mumol/l) with moderate @entity5 (1.3 g per 24 h), @entity12 (9.5 g per 24 h) and generalized @entity11 . Renal biopsy showed @entity9 ( @entity9 ) with severe mononuclear cell infiltration. No etiology was found. The @entity0 required hemodialysis (5 times) and responded dramatically to therapy with @entity2 (initially 75 mg per day), which was discontinued after 2 months. He presented again 11 weeks after admission with @entity10 of the right eye, and 2 months later with the same condition in the left eye. Response to local application of @entity3 was slow. The association of @entity9 with @entity8 has so far been reported in 12 other pediatric @entity0 aged 10 to 16 years, and in one adult @entity0 ; 64% were female. @entity8 often recurred, in contrast to @entity7 . The etiology of the syndrome is unknown, a transient defect in cell-mediated immunity being postulated.

title: [Acute @entity9 and XXXX : a recently recognized syndrome].

answer: @entity8


abstract: The case is described of a 14-year-old @entity0 who presented with a 6-week history of fatigue, severe @entity4 (15 kg) and @entity12 . On admission he was in non-oliguric @entity1 (serum @entity6 1360 mumol/l) with moderate @entity5 (1.3 g per 24 h), @entity12 (9.5 g per 24 h) and generalized @entity11 . Renal biopsy showed @entity9 ( @entity9 ) with severe mononuclear cell infiltration. No etiology was found. The @entity0 required hemodialysis (5 times) and responded dramatically to therapy with @entity2 (initially 75 mg per day), which was discontinued after 2 months. He presented again 11 weeks after admission with @entity10 of the right eye, and 2 months later with the same condition in the left eye. Response to local application of @entity3 was slow. The association of @entity9 with @entity8 has so far been reported in 12 other pediatric @entity0 aged 10 to 16 years, and in one adult @entity0 ; 64% were female. @entity8 often recurred, in contrast to @entity7 . The etiology of the syndrome is unknown, a transient defect in cell-mediated immunity being postulated.

title: [Acute XXXX and @entity8 : a recently recognized syndrome].

answer: @entity9


abstract: UNASSIGNED: To evaluate the efficacy and safety of anti-NGF antibody treatment in hip and @entity2 ( @entity1 ), a systematic review and meta-analysis was undertaken utilizing the criteria described by the Cochrane collaboration. Both published and unpublished trials were identified for tanezumab, fulranumab and fasinumab in hip and knee @entity1 ; sponsors were contacted to provide and confirm data. Study quality was assessed by Jadad criteria; efficacy and safety data were extracted independently by two individuals and meta-analyses were performed using Revman 5.2. 13 randomized, controlled trials were identified: 10 of tanezumab, two of fulranumab and one with fasinumab. All agents demonstrated superiority in efficacy compared to placebo. The highest doses in the phase II studies of tanezumab had a standardized effect size for @entity0 of 0.73 (CI, 0.51, 0.95). Subsequent phase III studies of tanezumab and phase II studies of fulranumab and fasinumab reported standardized effect sizes for WOMAC @entity0 .5, with no clear distinction among dose levels. Tanezumab compared to NSAIDs and opioids showed greater efficacy with a standardized effect size for @entity0 of 0.23 (CI 0.17-0.29). WOMAC function and PGA results were similar to @entity0 . Safety, determined by odds ratios of withdrawals from studies due to adverse events (AEs), was better at the lower doses than higher doses and similar among all agents. These results demonstrate that antibodies to NGF provide efficacy in @entity1 and that general safety at the lower doses appears similar to placebo. Additional data on both efficacy and safety of these antibodies are needed to define the optimal dose to maximize benefit to risk.

title: A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of XXXX of the hip or knee.

answer: @entity1


abstract: This phase II clinical trial was conducted in a series of @entity1 with @entity0 , refractory to conventional chemotherapy. The therapeutic regimen consisted of a combination of @entity3 100 mg/m2, given as a 24-hr infusion on day 1 and @entity4 (VDS) 2 mg/m2, i.v. bolus on days 1 and 8. VDS injection was omitted on day 8 in @entity1 with poor bone marrow reserves (prior extensive irradiation). Courses were repeated at 4-week intervals until documented disease progression. Among 46 evaluable @entity1 , there were two complete and seven partial remissions for an overall response rate of 20%. These responses lasted for a median of 21 weeks (range 8-89 weeks). Remission rates according to the predominant metastatic site were as follows: soft tissue, 3/8 (38%); bone, 0/6 (0%); viscera, 6/32 (19%). Transient myelosuppression and gastrointestinal intolerance were almost universal. @entity2 and neurologic manifestations were frequently encountered but these adverse reactions were generally mild. Significant antineoplastic activity in far-advanced and heavily pretreated @entity1 warrants further evaluation of this regimen at an earlier stage of the disease.

title: XXXX plus @entity4 in @entity0 : a phase II trial of the EORTC Breast Cancer Cooperative Group.

answer: @entity3


abstract: This phase II clinical trial was conducted in a series of @entity1 with @entity0 , refractory to conventional chemotherapy. The therapeutic regimen consisted of a combination of @entity3 100 mg/m2, given as a 24-hr infusion on day 1 and @entity4 (VDS) 2 mg/m2, i.v. bolus on days 1 and 8. VDS injection was omitted on day 8 in @entity1 with poor bone marrow reserves (prior extensive irradiation). Courses were repeated at 4-week intervals until documented disease progression. Among 46 evaluable @entity1 , there were two complete and seven partial remissions for an overall response rate of 20%. These responses lasted for a median of 21 weeks (range 8-89 weeks). Remission rates according to the predominant metastatic site were as follows: soft tissue, 3/8 (38%); bone, 0/6 (0%); viscera, 6/32 (19%). Transient myelosuppression and gastrointestinal intolerance were almost universal. @entity2 and neurologic manifestations were frequently encountered but these adverse reactions were generally mild. Significant antineoplastic activity in far-advanced and heavily pretreated @entity1 warrants further evaluation of this regimen at an earlier stage of the disease.

title: @entity3 plus @entity4 in XXXX : a phase II trial of the EORTC Breast Cancer Cooperative Group.

answer: @entity0


abstract: This phase II clinical trial was conducted in a series of @entity1 with @entity0 , refractory to conventional chemotherapy. The therapeutic regimen consisted of a combination of @entity3 100 mg/m2, given as a 24-hr infusion on day 1 and @entity4 (VDS) 2 mg/m2, i.v. bolus on days 1 and 8. VDS injection was omitted on day 8 in @entity1 with poor bone marrow reserves (prior extensive irradiation). Courses were repeated at 4-week intervals until documented disease progression. Among 46 evaluable @entity1 , there were two complete and seven partial remissions for an overall response rate of 20%. These responses lasted for a median of 21 weeks (range 8-89 weeks). Remission rates according to the predominant metastatic site were as follows: soft tissue, 3/8 (38%); bone, 0/6 (0%); viscera, 6/32 (19%). Transient myelosuppression and gastrointestinal intolerance were almost universal. @entity2 and neurologic manifestations were frequently encountered but these adverse reactions were generally mild. Significant antineoplastic activity in far-advanced and heavily pretreated @entity1 warrants further evaluation of this regimen at an earlier stage of the disease.

title: @entity3 plus XXXX in @entity0 : a phase II trial of the EORTC Breast Cancer Cooperative Group.

answer: @entity4


abstract: OBJECTIVE: To determine the feasibility of fertility preservation in adolescent males with @entity1 . DESIGN: Large multicenter retrospective study of male @entity0  <=20  years from 23 centers of a national network of sperm banks over a 34-year period. SETTING: Sperm banks. @entity0 (S): A total of 4,345 @entity0 and young @entity0 aged 11 to 20 years. INTERVENTION(S): Age, @entity1 diagnosis, feasibility of sperm banking, and sperm parameters. MAIN OUTCOME MEASURE(S): Description of @entity0 , and success of their fertility preservation. RESULT(S): We observed a mean yearly increase in referred @entity0 of 9.5% (95% confidence interval, 9.1%-9.8%) between 1973 and 2007. Over the study period, the percentage of younger @entity1 @entity0 who banked their sperm increased, especially in the 11-14  year age group, rising from 1% in 1986 to 9% in 2006. We found that 4,314 @entity0 attempted to produce a semen sample, 4,004 succeeded, and sperm was banked for 3,616. The mean total sperm count was 61.75 * 10(6) for the 11-14  year age group, and 138.81 * 10(6) for the 18-20  year age group. It was noteworthy that intercenter variations in practices involving young @entity0 seeking to preserve their fertility before @entity1 therapy were observed within this national network. CONCLUSION(S): Our results emphasize the need for decisive changes in public health policy to facilitate the access to reproductive health-care for young @entity1 @entity0 .

title: Sperm cryopreservation in adolescents and young adults with XXXX : results of the French national sperm banking network (CECOS).

answer: @entity1


abstract: OBJECTIVES: The natural progression of @entity3 in the Chinese population is not well researched. We investigated the progression of @entity2 over 4 years in 15-44-year-old Chinese villagers with no access to regular dental care. METHODS: In 1992, 486 villagers were enrolled, and in 1996, 413 villagers were re-examined. @entity0 ( @entity0 ) and clinical attachment level (CAL) were examined at six sites per tooth. Sites with   CAL >= 3mm were defined as active sites. Cross-sectional and longitudinal analyses were performed using means and percentile plots. RESULTS: The mean CAL increased by 0.26mm over 4 years. The incidence of @entity3 (at least one site with CAL >= 3mm) was 8%. The incidence of @entity3 among those with no @entity2 at baseline was 44.9%. Seventy-eight percent of the subjects had at least one active site. In the 15-24-year group, 244 of 401 active sites had @entity1 , while only 51 active sites had both @entity1 and deeper pockets. In the 25-34-year and 35-44-year groups, almost one-third of the active sites (329/1087) and more than one-third of the active sites (580/1312) respectively had a combination of @entity1 and deeper pockets. CONCLUSIONS: In this study, we demonstrated that in Chinese population without regular dental care, both the  initiation of @entity3 and progression of previously existed @entity3 contributed to  the natural progression of @entity3 and periodontal pocketing played a greater role with age increasing. CLINICAL SIGNIFICANCE: This rare study reports the natural progression of @entity2 in a group of Chinese villagers (15-44 years) with virtually no access to regular dental care.

title: A 4-year prospective study of the progression of XXXX in a rural Chinese population.

answer: @entity2


abstract: UNASSIGNED: BMPs expressed in the ovary differentially regulate steroidogenesis by granulosa cells. BMP-9, a circulating BMP, is associated with cell proliferation, apoptosis and differentiation in various tissues. However, the effects of BMP-9 on ovarian function have yet to be elucidated. Here we investigated BMP-9 actions on steroidogenesis using @entity0 primary granulosa cells. BMP-9 potently suppressed FSH-induced @entity3 production, whereas it did not affect FSH-induced @entity1 production by granulosa cells. The effects of BMP-9 on FSH-induced steroidogenesis were not influenced by the presence of oocytes. FSH-induced @entity2 synthesis and FSH-induced mRNA expression of steroidogenic factors, including StAR, P450scc, 3bHSD2 and @entity6 , were suppressed by treatment with BMP-9. BMP-9 mRNA expression was detected in granulosa cells but not in oocytes. BMP-9 readily activated @entity4 /8 phosphorylation and Id-1 transcription in granulosa cells. Analysis using ALK inhibitors indicated that BMP-9 actions were mediated via type-I receptors other than ALK-2, -3 and -6. Furthermore, experiments using extracellular domains (ECDs) for BMP type-I and -II receptor constructs revealed that the effects of BMP-9 were reversed by ECDs for ALK-1 and @entity5 . Thus, the functional receptors for BMP-9 in granulosa cells were most likely to be the complex of ALK-1 and @entity5 . Collectively, the results of the present study showed that BMP-9 can affect luteinization and that there are two possible sources of BMP-9, serum and granulosa cells in the ovary.

title: Regulatory role of BMP-9 in steroidogenesis by XXXX ovarian granulosa cells.

answer: @entity0


abstract: OBJECTIVE: To explore the mutational status of @entity4 , @entity5 and @entity10 genes in @entity3 negative @entity1 ( @entity1 ) @entity0 and the clinical features of @entity1 @entity0 with these mutations. METHODS: A total of 246 @entity0 with a definite diagnosis of @entity3 negative @entity1 were enrolled from January 2009 to January 2014 into this study. Among them, there were 48 cases of @entity8 ( @entity8 ) @entity0 , 171 cases of @entity9 ( @entity9 ) @entity0 and 27 cases of @entity7 ( @entity7 ) @entity0 . And @entity4 , @entity5 @entity6 , 12 exons of @entity5 and @entity10 @entity11 /K genes were amplified by PCR and sequenced directly. Clinical features were also analyzed in @entity0 . RESULTS: Among 246 cases of @entity3 -negative @entity1 @entity0 , 52 cases (21.1%) had @entity4 mutation, 121 cases (49.2%) @entity5 @entity6 mutation, 0 case (0) 12 exons of @entity5 mutation, and 2 cases (0.8%) @entity10 @entity11 /K mutation, respectively. These mutations were found existing exclusively. In @entity8 @entity0 , the white blood cell and platelet counts in @entity5 @entity6 mutated group were higher than those in wild-type @entity5 @entity6 group, while the level of hemoglobin was higher in wild-type @entity5 @entity6 group (all P < 0.05). In @entity9 @entity0 , the white blood cell count, the level of hemoglobin, the frequency of @entity2 events and risk stratification in @entity5 @entity6 mutated group were higher than those in @entity4 mutated group (all P < 0.05). In @entity7 @entity0 , the level of hemoglobin in @entity5 @entity6 mutated group were significantly higher than those in @entity4 mutated group (P < 0.05). CONCLUSIONS: The proliferative level of bone marrow, risk of @entity2 events and stratification are lower in @entity4 mutated @entity0 than those in @entity5 @entity6 mutated @entity0 . The pathogenic mechanism of mutated gene should be further investigated in future.

title: [Analysis of @entity4 , XXXX and @entity10 gene mutations in @entity3 negative @entity1 ].

answer: @entity5


abstract: OBJECTIVE: To explore the mutational status of @entity4 , @entity5 and @entity10 genes in @entity3 negative @entity1 ( @entity1 ) @entity0 and the clinical features of @entity1 @entity0 with these mutations. METHODS: A total of 246 @entity0 with a definite diagnosis of @entity3 negative @entity1 were enrolled from January 2009 to January 2014 into this study. Among them, there were 48 cases of @entity8 ( @entity8 ) @entity0 , 171 cases of @entity9 ( @entity9 ) @entity0 and 27 cases of @entity7 ( @entity7 ) @entity0 . And @entity4 , @entity5 @entity6 , 12 exons of @entity5 and @entity10 @entity11 /K genes were amplified by PCR and sequenced directly. Clinical features were also analyzed in @entity0 . RESULTS: Among 246 cases of @entity3 -negative @entity1 @entity0 , 52 cases (21.1%) had @entity4 mutation, 121 cases (49.2%) @entity5 @entity6 mutation, 0 case (0) 12 exons of @entity5 mutation, and 2 cases (0.8%) @entity10 @entity11 /K mutation, respectively. These mutations were found existing exclusively. In @entity8 @entity0 , the white blood cell and platelet counts in @entity5 @entity6 mutated group were higher than those in wild-type @entity5 @entity6 group, while the level of hemoglobin was higher in wild-type @entity5 @entity6 group (all P < 0.05). In @entity9 @entity0 , the white blood cell count, the level of hemoglobin, the frequency of @entity2 events and risk stratification in @entity5 @entity6 mutated group were higher than those in @entity4 mutated group (all P < 0.05). In @entity7 @entity0 , the level of hemoglobin in @entity5 @entity6 mutated group were significantly higher than those in @entity4 mutated group (P < 0.05). CONCLUSIONS: The proliferative level of bone marrow, risk of @entity2 events and stratification are lower in @entity4 mutated @entity0 than those in @entity5 @entity6 mutated @entity0 . The pathogenic mechanism of mutated gene should be further investigated in future.

title: [Analysis of @entity4 , @entity5 and @entity10 gene mutations in XXXX negative @entity1 ].

answer: @entity3


abstract: OBJECTIVE: To explore the mutational status of @entity4 , @entity5 and @entity10 genes in @entity3 negative @entity1 ( @entity1 ) @entity0 and the clinical features of @entity1 @entity0 with these mutations. METHODS: A total of 246 @entity0 with a definite diagnosis of @entity3 negative @entity1 were enrolled from January 2009 to January 2014 into this study. Among them, there were 48 cases of @entity8 ( @entity8 ) @entity0 , 171 cases of @entity9 ( @entity9 ) @entity0 and 27 cases of @entity7 ( @entity7 ) @entity0 . And @entity4 , @entity5 @entity6 , 12 exons of @entity5 and @entity10 @entity11 /K genes were amplified by PCR and sequenced directly. Clinical features were also analyzed in @entity0 . RESULTS: Among 246 cases of @entity3 -negative @entity1 @entity0 , 52 cases (21.1%) had @entity4 mutation, 121 cases (49.2%) @entity5 @entity6 mutation, 0 case (0) 12 exons of @entity5 mutation, and 2 cases (0.8%) @entity10 @entity11 /K mutation, respectively. These mutations were found existing exclusively. In @entity8 @entity0 , the white blood cell and platelet counts in @entity5 @entity6 mutated group were higher than those in wild-type @entity5 @entity6 group, while the level of hemoglobin was higher in wild-type @entity5 @entity6 group (all P < 0.05). In @entity9 @entity0 , the white blood cell count, the level of hemoglobin, the frequency of @entity2 events and risk stratification in @entity5 @entity6 mutated group were higher than those in @entity4 mutated group (all P < 0.05). In @entity7 @entity0 , the level of hemoglobin in @entity5 @entity6 mutated group were significantly higher than those in @entity4 mutated group (P < 0.05). CONCLUSIONS: The proliferative level of bone marrow, risk of @entity2 events and stratification are lower in @entity4 mutated @entity0 than those in @entity5 @entity6 mutated @entity0 . The pathogenic mechanism of mutated gene should be further investigated in future.

title: [Analysis of @entity4 , @entity5 and @entity10 gene mutations in @entity3 negative XXXX ].

answer: @entity1


abstract: OBJECTIVE: To explore the mutational status of @entity4 , @entity5 and @entity10 genes in @entity3 negative @entity1 ( @entity1 ) @entity0 and the clinical features of @entity1 @entity0 with these mutations. METHODS: A total of 246 @entity0 with a definite diagnosis of @entity3 negative @entity1 were enrolled from January 2009 to January 2014 into this study. Among them, there were 48 cases of @entity8 ( @entity8 ) @entity0 , 171 cases of @entity9 ( @entity9 ) @entity0 and 27 cases of @entity7 ( @entity7 ) @entity0 . And @entity4 , @entity5 @entity6 , 12 exons of @entity5 and @entity10 @entity11 /K genes were amplified by PCR and sequenced directly. Clinical features were also analyzed in @entity0 . RESULTS: Among 246 cases of @entity3 -negative @entity1 @entity0 , 52 cases (21.1%) had @entity4 mutation, 121 cases (49.2%) @entity5 @entity6 mutation, 0 case (0) 12 exons of @entity5 mutation, and 2 cases (0.8%) @entity10 @entity11 /K mutation, respectively. These mutations were found existing exclusively. In @entity8 @entity0 , the white blood cell and platelet counts in @entity5 @entity6 mutated group were higher than those in wild-type @entity5 @entity6 group, while the level of hemoglobin was higher in wild-type @entity5 @entity6 group (all P < 0.05). In @entity9 @entity0 , the white blood cell count, the level of hemoglobin, the frequency of @entity2 events and risk stratification in @entity5 @entity6 mutated group were higher than those in @entity4 mutated group (all P < 0.05). In @entity7 @entity0 , the level of hemoglobin in @entity5 @entity6 mutated group were significantly higher than those in @entity4 mutated group (P < 0.05). CONCLUSIONS: The proliferative level of bone marrow, risk of @entity2 events and stratification are lower in @entity4 mutated @entity0 than those in @entity5 @entity6 mutated @entity0 . The pathogenic mechanism of mutated gene should be further investigated in future.

title: [Analysis of @entity4 , @entity5 and XXXX gene mutations in @entity3 negative @entity1 ].

answer: @entity10


abstract: OBJECTIVE: To explore the mutational status of @entity4 , @entity5 and @entity10 genes in @entity3 negative @entity1 ( @entity1 ) @entity0 and the clinical features of @entity1 @entity0 with these mutations. METHODS: A total of 246 @entity0 with a definite diagnosis of @entity3 negative @entity1 were enrolled from January 2009 to January 2014 into this study. Among them, there were 48 cases of @entity8 ( @entity8 ) @entity0 , 171 cases of @entity9 ( @entity9 ) @entity0 and 27 cases of @entity7 ( @entity7 ) @entity0 . And @entity4 , @entity5 @entity6 , 12 exons of @entity5 and @entity10 @entity11 /K genes were amplified by PCR and sequenced directly. Clinical features were also analyzed in @entity0 . RESULTS: Among 246 cases of @entity3 -negative @entity1 @entity0 , 52 cases (21.1%) had @entity4 mutation, 121 cases (49.2%) @entity5 @entity6 mutation, 0 case (0) 12 exons of @entity5 mutation, and 2 cases (0.8%) @entity10 @entity11 /K mutation, respectively. These mutations were found existing exclusively. In @entity8 @entity0 , the white blood cell and platelet counts in @entity5 @entity6 mutated group were higher than those in wild-type @entity5 @entity6 group, while the level of hemoglobin was higher in wild-type @entity5 @entity6 group (all P < 0.05). In @entity9 @entity0 , the white blood cell count, the level of hemoglobin, the frequency of @entity2 events and risk stratification in @entity5 @entity6 mutated group were higher than those in @entity4 mutated group (all P < 0.05). In @entity7 @entity0 , the level of hemoglobin in @entity5 @entity6 mutated group were significantly higher than those in @entity4 mutated group (P < 0.05). CONCLUSIONS: The proliferative level of bone marrow, risk of @entity2 events and stratification are lower in @entity4 mutated @entity0 than those in @entity5 @entity6 mutated @entity0 . The pathogenic mechanism of mutated gene should be further investigated in future.

title: [Analysis of XXXX , @entity5 and @entity10 gene mutations in @entity3 negative @entity1 ].

answer: @entity4


abstract: UNASSIGNED: Significant changes of @entity1 @entity0 during inpatient treatment were evalutaed and compared to established outcome criteria. The concept of reliable and clinically significant change methods was applied to three hundred and ninety-six @entity0 suffering from a @entity1 spectrum disorder. First, information on whether or not the change of the @entity0 's condition is sufficient in order to declare that it is beyond a measurement error or random effect (= reliable change) was evaluated and in a second step it was observed if the reliable change was clinically meaningful (= clinically significant change). Different Positive and Negative Syndrome Scale for @entity1 (PANSS) thresholds were applied to define the clinically significant change (40, 45 and 50 points). These changes were then compared to established outcome criteria such as response and remission. Seventy-nine of the 396 @entity0 (20%) showed a reliable improvement of symptoms, whereas 70% improved without achieving a reliable change of their condition. Of the 79 @entity0 achieving a reliable change during treatment 8-15% concurrently showed a clinically significant change depending on the respective PANSS threshold. In contrast, 56% of the @entity0 achieved response and 60% were in remission at discharge when applying established outcome criteria. Our results showed that a rather small number of @entity1 @entity0 were found to reliably change during inpatient treatment, with even less @entity0 achieving a clinically significant change. The concept of reliable and clinically significant changes revealed to be a lot more stringent than today's established outcome criteria and should be critically evaluated regarding its use in @entity1 @entity0 . Copyright    2015 John Wiley _ Sons, Ltd.

title: Challenging the understanding of significant improvement and outcome in XXXX - the concept of reliable and clinically significant change methods.

answer: @entity1


abstract: UNASSIGNED: @entity4 ( @entity4 ) is the most common cause of @entity2 in Nepal. The aim of the present study is to determine the clinical presentation and histological pattern of @entity4 with and without immunofluorescence (IF). It is a retrospective analysis of all @entity4 @entity0 with kidney biopsy at the Bir Hospital from January 2000 to April 2009. The clinical presentation, blood pressure, urine analysis, 24-h urinary protein, biochemistry, hemoglobin, antinuclear antibody, anti-ds DNA, light microscopy (LM) and IF findings of kidney biopsies were computed from hospital records. SPSS package was used for analysis. A total of 398 @entity0 [LM 204 (51%) and LM plus IF 194 (49%] were analyzed. The mean age of the study @entity0 was 28    13.6 years (range 7-74); males comprised 52.8% and females 47.2% of the @entity0 ; 51% were between 16 and 30 years of age. The common clinical presentations included @entity6 ( @entity6 ), seen in 69% of the @entity0 , followed by @entity5 , seen in 14.4% of the @entity0 . Kidney biopsy without IF showed mesangial proliferative @entity4 (MesPGN) in 21.1%, @entity4 ( @entity9 ) in 18.6%, @entity1 ( @entity1 ) in 14.2%, @entity7 ( @entity7 ) in 12.3% and @entity3 ( @entity3 ) in 9.8% of the cases. With IF, @entity7 was seen in 23.2%, @entity3 in 18%, @entity1 in 11.9%, @entity1 in 9.8%, MesPGN in 8.2%, @entity9 in 4.1% and crescentic @entity4 in 3.1% of the cases. @entity8 in the cases @entity4 was most common in young adults, with the majority presenting with @entity6 . @entity7 and @entity3 were the most common glomerular lesions; over-diagnosis of MesPGN and @entity9 by LM could be due to exclusion of @entity1 .

title: Pattern of XXXX in Nepal: A single-center experience.

answer: @entity1


abstract: BACKGROUND: @entity7 is the major nongenetic cause of @entity4 at birth and beyond. Among other pathologies, there is a striking @entity3 / @entity5 of organ of Corti hair and supporting cells. METHODS: Using an in vitro embryonic @entity1 model of @entity7 -induced cochlear teratogenesis that mimics the known @entity0 pathology, and functional signaling network modeling, we tested the hypothesis that @entity7 disrupts the highly ordered organ of Corti hair and supporting cells pattern by dysregulating Notch and @entity6 , their cognate ligands and downstream effectors. RESULTS: Several novel emergent properties of the critical lateral inhibition subnetwork became apparent. The subnetwork has classic small-world properties such as short paths between most gene pairs, few long-distance links, and considerable clustering. Concomitantly, the calculated probability that our specific gene expression dataset is from dysplastic organs of Corti is highly significant (p   <   1 * 10(-12) ). Furthermore, we determined that the subnetwork has a highly heterogeneous scale-free topology in which the highly linked genes (hubs), Notch and @entity6 , play a central role in mediating interactions among the less linked genes. CONCLUSION: This phenomenon has important biologic and therapeutic implications. @entity2 Research (Part A) 103:573-582, 2015.    2015 Wiley Periodicals, Inc.

title: CMV-induced embryonic @entity1 organ of corti XXXX : Network architecture of dysfunctional lateral inhibition.

answer: @entity3


abstract: BACKGROUND: @entity7 is the major nongenetic cause of @entity4 at birth and beyond. Among other pathologies, there is a striking @entity3 / @entity5 of organ of Corti hair and supporting cells. METHODS: Using an in vitro embryonic @entity1 model of @entity7 -induced cochlear teratogenesis that mimics the known @entity0 pathology, and functional signaling network modeling, we tested the hypothesis that @entity7 disrupts the highly ordered organ of Corti hair and supporting cells pattern by dysregulating Notch and @entity6 , their cognate ligands and downstream effectors. RESULTS: Several novel emergent properties of the critical lateral inhibition subnetwork became apparent. The subnetwork has classic small-world properties such as short paths between most gene pairs, few long-distance links, and considerable clustering. Concomitantly, the calculated probability that our specific gene expression dataset is from dysplastic organs of Corti is highly significant (p   <   1 * 10(-12) ). Furthermore, we determined that the subnetwork has a highly heterogeneous scale-free topology in which the highly linked genes (hubs), Notch and @entity6 , play a central role in mediating interactions among the less linked genes. CONCLUSION: This phenomenon has important biologic and therapeutic implications. @entity2 Research (Part A) 103:573-582, 2015.    2015 Wiley Periodicals, Inc.

title: CMV-induced embryonic XXXX organ of corti @entity3 : Network architecture of dysfunctional lateral inhibition.

answer: @entity1


abstract: BACKGROUND: Secretoglobin ( @entity6 , a cytokine-like secretory protein of small molecular weight, is predominantly expressed in airway epithelial cells. While @entity6 is known to have anti-inflammatory, growth factor, and anti-fibrotic activities, whether @entity6 has any other roles, particularly in lung homeostasis and disease has not been demonstrated in vivo. The aim of this study was to address these questions in @entity1 . METHODS: A transgenic @entity1 line that expresses @entity6 in the lung using the @entity0 surfactant protein-C promoter was established. Detailed histological, immunohistochemical, physiological, and molecular characterization of the @entity6 -transgenic @entity1 lungs were carried out. @entity6 -transgenic and wild-type @entity1 were subjected to @entity4 -induced @entity5 model, and their lungs and bronchoalveolar lavage fluids were collected at various time points during 9  weeks post- @entity4 treatment for further analysis. RESULTS: Adult @entity6 -transgenic @entity1 lungs expressed approximately five-fold higher levels of @entity6 protein in comparison to wild-type @entity1 as determined by western blotting of lung tissues. Immunohistochemistry showed that expression was localized to alveolar type II cells in addition to airway epithelial cells, thus accurately reflecting the site of surfactant protein-C expression. @entity6 - @entity1 showed normal lung development and histology, and no overt gross phenotypes. However, when subjected to a @entity4 -induced @entity5 model, they initially exhibited exacerbated @entity2 at 3  weeks post- @entity4 administration that was more rapidly resolved by 6  weeks as compared with wild-type @entity1 , as determined by lung histology, Masson Trichrome staining and @entity3 content, inflammatory cell numbers, expression of collagen genes, and proinflammatory cytokine levels. The decrease of @entity2 coincided with the increased expression of @entity6 in @entity6 -transgenic lungs. CONCLUSIONS: These results demonstrate that @entity6 is an anti-fibrotic agent, and suggest a possible therapeutic use of recombinant @entity6 in the treatment of @entity5 .

title: Transgenically-expressed secretoglobin 3A2 accelerates resolution of @entity4 -induced XXXX in @entity1 .

answer: @entity5


abstract: BACKGROUND: Secretoglobin ( @entity6 , a cytokine-like secretory protein of small molecular weight, is predominantly expressed in airway epithelial cells. While @entity6 is known to have anti-inflammatory, growth factor, and anti-fibrotic activities, whether @entity6 has any other roles, particularly in lung homeostasis and disease has not been demonstrated in vivo. The aim of this study was to address these questions in @entity1 . METHODS: A transgenic @entity1 line that expresses @entity6 in the lung using the @entity0 surfactant protein-C promoter was established. Detailed histological, immunohistochemical, physiological, and molecular characterization of the @entity6 -transgenic @entity1 lungs were carried out. @entity6 -transgenic and wild-type @entity1 were subjected to @entity4 -induced @entity5 model, and their lungs and bronchoalveolar lavage fluids were collected at various time points during 9  weeks post- @entity4 treatment for further analysis. RESULTS: Adult @entity6 -transgenic @entity1 lungs expressed approximately five-fold higher levels of @entity6 protein in comparison to wild-type @entity1 as determined by western blotting of lung tissues. Immunohistochemistry showed that expression was localized to alveolar type II cells in addition to airway epithelial cells, thus accurately reflecting the site of surfactant protein-C expression. @entity6 - @entity1 showed normal lung development and histology, and no overt gross phenotypes. However, when subjected to a @entity4 -induced @entity5 model, they initially exhibited exacerbated @entity2 at 3  weeks post- @entity4 administration that was more rapidly resolved by 6  weeks as compared with wild-type @entity1 , as determined by lung histology, Masson Trichrome staining and @entity3 content, inflammatory cell numbers, expression of collagen genes, and proinflammatory cytokine levels. The decrease of @entity2 coincided with the increased expression of @entity6 in @entity6 -transgenic lungs. CONCLUSIONS: These results demonstrate that @entity6 is an anti-fibrotic agent, and suggest a possible therapeutic use of recombinant @entity6 in the treatment of @entity5 .

title: Transgenically-expressed secretoglobin 3A2 accelerates resolution of XXXX -induced @entity5 in @entity1 .

answer: @entity4


abstract: BACKGROUND: Secretoglobin ( @entity6 , a cytokine-like secretory protein of small molecular weight, is predominantly expressed in airway epithelial cells. While @entity6 is known to have anti-inflammatory, growth factor, and anti-fibrotic activities, whether @entity6 has any other roles, particularly in lung homeostasis and disease has not been demonstrated in vivo. The aim of this study was to address these questions in @entity1 . METHODS: A transgenic @entity1 line that expresses @entity6 in the lung using the @entity0 surfactant protein-C promoter was established. Detailed histological, immunohistochemical, physiological, and molecular characterization of the @entity6 -transgenic @entity1 lungs were carried out. @entity6 -transgenic and wild-type @entity1 were subjected to @entity4 -induced @entity5 model, and their lungs and bronchoalveolar lavage fluids were collected at various time points during 9  weeks post- @entity4 treatment for further analysis. RESULTS: Adult @entity6 -transgenic @entity1 lungs expressed approximately five-fold higher levels of @entity6 protein in comparison to wild-type @entity1 as determined by western blotting of lung tissues. Immunohistochemistry showed that expression was localized to alveolar type II cells in addition to airway epithelial cells, thus accurately reflecting the site of surfactant protein-C expression. @entity6 - @entity1 showed normal lung development and histology, and no overt gross phenotypes. However, when subjected to a @entity4 -induced @entity5 model, they initially exhibited exacerbated @entity2 at 3  weeks post- @entity4 administration that was more rapidly resolved by 6  weeks as compared with wild-type @entity1 , as determined by lung histology, Masson Trichrome staining and @entity3 content, inflammatory cell numbers, expression of collagen genes, and proinflammatory cytokine levels. The decrease of @entity2 coincided with the increased expression of @entity6 in @entity6 -transgenic lungs. CONCLUSIONS: These results demonstrate that @entity6 is an anti-fibrotic agent, and suggest a possible therapeutic use of recombinant @entity6 in the treatment of @entity5 .

title: Transgenically-expressed secretoglobin 3A2 accelerates resolution of @entity4 -induced @entity5 in XXXX .

answer: @entity1


abstract: INTRODUCTION: To identify changes in @entity1 levels and its pathway (Jak/ @entity3 ) in the @entity0 placenta during preterm and term labor, placental tissues were collected from primiparous @entity0 who underwent vaginal deliveries or cesarean sections in our hospital. The @entity0 were divided into three groups: @entity2 (n  =  15), term labor (n  =  15), and term not in labor (n  =  15). MATERIAL AND METHODS: @entity1 levels were detected by ELISA in placental supernatant, and p- @entity3 and @entity4 protein was detected by Western blot. TUNEL was used to detect apoptosis in trophoblasts. HTR-8/SVneo cells were cultured after stimulation with @entity1 , and we measured p- @entity3 , @entity4 , and the rate of apoptosis. RESULTS: Expression of p- @entity3 and @entity4 in the placenta and trophoblast cells showed that @entity1 levels were highest in the @entity2 group and lowest in the term not in labor group. The highest expression of placental @entity4 protein was observed in the @entity2 group. More apoptotic cells were found in the @entity2 group than in the other two groups by TUNEL. @entity4 and p- @entity3 expression was significantly upregulated after stimulation by @entity1 in trophoblast cells in a dose-dependent manner. However, p- @entity3 was significantly decreased after 50  ng/mL and 100  ng/mL @entity1 for 72  h. A significant increase of apoptosis was observed with treatment of 50  ng/mL @entity1 in HTR-8/SVneo cells. CONCLUSIONS: The role of the @entity4 protein in the Jak/ @entity3 pathway is to mediate different mechanisms for preterm and term labor processes in the placenta.

title: Role of XXXX in the Jak/ @entity3 pathway in the @entity0 placenta: different mechanisms for preterm and term labor.

answer: @entity4


abstract: INTRODUCTION: To identify changes in @entity1 levels and its pathway (Jak/ @entity3 ) in the @entity0 placenta during preterm and term labor, placental tissues were collected from primiparous @entity0 who underwent vaginal deliveries or cesarean sections in our hospital. The @entity0 were divided into three groups: @entity2 (n  =  15), term labor (n  =  15), and term not in labor (n  =  15). MATERIAL AND METHODS: @entity1 levels were detected by ELISA in placental supernatant, and p- @entity3 and @entity4 protein was detected by Western blot. TUNEL was used to detect apoptosis in trophoblasts. HTR-8/SVneo cells were cultured after stimulation with @entity1 , and we measured p- @entity3 , @entity4 , and the rate of apoptosis. RESULTS: Expression of p- @entity3 and @entity4 in the placenta and trophoblast cells showed that @entity1 levels were highest in the @entity2 group and lowest in the term not in labor group. The highest expression of placental @entity4 protein was observed in the @entity2 group. More apoptotic cells were found in the @entity2 group than in the other two groups by TUNEL. @entity4 and p- @entity3 expression was significantly upregulated after stimulation by @entity1 in trophoblast cells in a dose-dependent manner. However, p- @entity3 was significantly decreased after 50  ng/mL and 100  ng/mL @entity1 for 72  h. A significant increase of apoptosis was observed with treatment of 50  ng/mL @entity1 in HTR-8/SVneo cells. CONCLUSIONS: The role of the @entity4 protein in the Jak/ @entity3 pathway is to mediate different mechanisms for preterm and term labor processes in the placenta.

title: Role of @entity4 in the Jak/ XXXX pathway in the @entity0 placenta: different mechanisms for preterm and term labor.

answer: @entity3


abstract: INTRODUCTION: To identify changes in @entity1 levels and its pathway (Jak/ @entity3 ) in the @entity0 placenta during preterm and term labor, placental tissues were collected from primiparous @entity0 who underwent vaginal deliveries or cesarean sections in our hospital. The @entity0 were divided into three groups: @entity2 (n  =  15), term labor (n  =  15), and term not in labor (n  =  15). MATERIAL AND METHODS: @entity1 levels were detected by ELISA in placental supernatant, and p- @entity3 and @entity4 protein was detected by Western blot. TUNEL was used to detect apoptosis in trophoblasts. HTR-8/SVneo cells were cultured after stimulation with @entity1 , and we measured p- @entity3 , @entity4 , and the rate of apoptosis. RESULTS: Expression of p- @entity3 and @entity4 in the placenta and trophoblast cells showed that @entity1 levels were highest in the @entity2 group and lowest in the term not in labor group. The highest expression of placental @entity4 protein was observed in the @entity2 group. More apoptotic cells were found in the @entity2 group than in the other two groups by TUNEL. @entity4 and p- @entity3 expression was significantly upregulated after stimulation by @entity1 in trophoblast cells in a dose-dependent manner. However, p- @entity3 was significantly decreased after 50  ng/mL and 100  ng/mL @entity1 for 72  h. A significant increase of apoptosis was observed with treatment of 50  ng/mL @entity1 in HTR-8/SVneo cells. CONCLUSIONS: The role of the @entity4 protein in the Jak/ @entity3 pathway is to mediate different mechanisms for preterm and term labor processes in the placenta.

title: Role of @entity4 in the Jak/ @entity3 pathway in the XXXX placenta: different mechanisms for preterm and term labor.

answer: @entity0